David B. Allison has, anticipates, or has had financial interests with the Frontiers Foundation; Vivus, Inc.; Kraft Foods; University of Wisconsin; University of Arizona; Paul, Weiss, Wharton and Garrison LLP; and Sage. In the last 36months, Christoph U. Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; AstraZeneca, Biotis, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Desitin, Eli Lilly, GSK, IntraCellular Therapies, Lundbeck, Medavante, Medicure, Medscape, Merck, National Institute of Mental Health, Novartis, Ortho-McNeill/Janssen/J&J, Otsuka, Pfizer, ProPhase, Schering-Plough, Sepracor/Sunovion, Supernus, Takeda, Teva, and Vanda. He has received research support from BMS, Feinstein Institute for Medical Research, Janssen/J&J, National Institute of Mental Health (NIMH), National Alliance for Research in Schizophrenia and Depression (NARSAD), and Otsuka. Stephen Crystal, Emily J. Dhurandhar, and Julia M. Gohlke declare no commercial or financial relationships that could be construed as a potential conflict of interest. In the past 3 years, Elaine H. Morrato has received research support from Janssen Pharmaceuticals, Inc and Pfizer, Inc. In the last 12months, Henry A. Nasrallah received research support from Forest, Lilly Otsuka, Roche and Shire and served as a consultant for Genentech, Janssen, Merck, Novartis, Sunovion, Gruenthal, Boehringer-Ingelheim, and Lundbeck and was on the speakers bureau of Janssen, Merck, Novartis, and Sunovion. In the last 36months, JWN has received research support from NIMH, Bristol-Myers Squibb, and Pfizer, Inc. He has received consultant fees and/or been on data safety monitoring committees for AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, BioVail, H. Lundbeck, Janssen Pharmaceutica, Obecure, Otsuka Pharmaceuticals, Sepracor, Inc., Solvay Pharma, Inc., Teva Pharmaceutical, Dainippon Sumitomo Pharma America, Inc., Organon Pharmaceuticals USA Inc., Schering-Plough/Merck, Vivus, Inc., Consultant to Litigation and Boehringer-Ingelheim. He has received royalties/patents/other income from Compact Clinicals/Jones and Bartlett Publishing. Ginger Nicol is Instructor of Child Psychiatry at Washington University in St. Louis, MO, USA and has no significant financial conflict of interest in compliance with the Washington University School of Medicine Conflict of Interest Policy. Ginger Nicol has received research funding from the NIMH, NARSAD, the Dana Brown Charitable Trust Foundation, the Sidney R. Baer, Jr. Foundation, and the CHADS Coalition for Mental Health. She also receives grant support from Pfizer, Inc. for an investigator-initiated clinical trial. She receives royalties from Jones & Barlett Learning for development of a pediatric metabolic monitoring form and has consulted to MedScape. In the last 3 years, Gary Remington has received research support from the following external funding agencies: Canadian Institutes of Health Research (CIHR), Schizophrenia Society of Ontario (SSO), and the Canadian Diabetes Association (CDA). He has also received support from Novartis Canada, Medicure Inc., and Neurocrine Bioscience. He has received consultant fees from Laboratorios Farmacéuticos ROVI, Novartis, and Roche, as well as speaker’s fees from Novartis.